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INTRODUCTION
Asthma and chronic obstructive pulmonary disease (COPD) 
are pulmonary disorders characterized by various degrees of 
airflow limitation, inflammation, and tissue remodeling. Bron-
chial asthma, an allergic disease that develops in childhood, is 
physiologically characterized by reversible airflow obstruction. 
It has an episodic course and a generally favorable prognosis, 
as it responds well to anti-inflammatory treatment.
1 In contrast, 
pure COPD is caused by tobacco smoke, develops in mid-life or 
later, and is characterized by incompletely reversible airflow lim-
itation that results in a progressive decline in lung function and 
leads to premature death. These definitions describe the physi-
ological and anatomic extremes of asthma and COPD, and al-
low them to be recognized as distinct disease entities. However, 
in clinical practice, many older patients have pathobiological 
and symptomatic features of both diseases, necessitating a re-
evaluation of the concept of COPD and asthma as separate con-
ditions.
2,3 Asthma and COPD are both chronic inflammatory 
lung diseases. In both conditions, inflammation is associated 
with structural alterations at large and small airway levels.
4,5 This 
can result in a transient phenotypic overlap or a combined syn-
drome with characteristics of both diseases.
In this review, we focus on the inflammatory mechanisms of 
asthma and COPD. We address: i) the importance of the over-
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lap between asthma and COPD; ii) their episodic or transient 
overlap; iii) their structural similarities; and iv) common thera-
peutic targets for both conditions.
 
WHAT IS THE OVERLAP BETWEEN ASTHMA AND COPD?
A patient who has features of more than one condition exhib-
its an overlap syndrome.
6 The pathogenesis of overlapping asth-
ma and COPD may be mediated by inflammatory/immune 
mechanisms and/or structural alterations. The clinical recogni-
tion of overlapping asthma and COPD requires an assessment 
of increased variability of airflow and incompletely reversible 
airflow obstruction.
6 Numerous studies have documented the 
presence of partial reversibility after short-term and long-term 
bronchodilator administration in patients with COPD.
7,8 Current 
guidelines emphasize a fixed or irreversible component to air-
way obstruction in some patients with asthma.
9,10 Thus, the use 
of phenotypic characteristics (e.g., symptoms, allergy, bronchi-
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al hyperresponsiveness) may be useful in differentiating disease 
characteristics and in understanding similarities in the devel-
opment and progression of both obstructive airway diseases. A 
recent study found that 17% to 19% of patients with obstructive 
airway diseases had more than one condition, or overlap.
11 The 
overlap of asthma and COPD has been confirmed in older pa-
tients by objective testing and is becoming an important clini-
cal consideration.
12
The distinction between the inflammatory profiles of asthma 
and COPD may be blurred under certain circumstances. Classi-
cally, asthmatic airways show a CD4
+ lymphocyte-, eosinophil-, 
and macrophage-rich inflammatory response, whereas promi-
nent increases in CD8
+ T cells, neutrophils, and macrophages 
are seen in the bronchioles and alveoli in COPD. However, com-
pared with mild and moderate asthmatics, severe asthmatics or 
asthmatics who smoke show higher numbers of neutrophils in 
bronchoalveolar lavage fluid and biopsies.
13,14 Conversely, in 
COPD patients, especially those with acute disease exacerba-
tions, tissue eosinophilia is common
15 and is associated with a 
favorable response to steroid therapy.
16
In asthmatics, there is a predominance of Th2 cytokines, in-
cluding interleukin (IL)-4, IL-5, and IL-13, and upregulation of 
chemokines, including regulated on activation, normal T-cell-
expressed and secreted (RANTES), eotaxins, and monocyte che-
moattractant protein-1.
17 In contrast, Th1-dominated responses 
such as enhanced production of interferon-γ by CD8
+ cells have 
been documented in COPD patients. Additionally, the main in-
flammatory mediators involved in the pathogenesis of tissue 
inflammation in COPD are the neutrophil chemokine IL-8, leu-
kotriene B4, IL-1, and tumor necrosis factor-α.
4,18,19 However, in 
some COPD subjects, the levels of tumor necrosis factor-α indi-
cated the presence of asthma,
20,21 and allergic inflammatory me-
diators such as IL-4, IL-5, and IL-13 were produced, particular-
ly during exacerbations.
Alveolar inflammation and the development of lung emphy-
sema are major characteristics of COPD. The distal lung, includ-
ing the alveolar parenchyma, is an important site of inflamma-
tion in asthma, although asthma is classically considered as a 
chronic inflammatory disease of the airways.
22,23 Remodeling of 
various structural components such as airway epithelium, air-
way smooth muscle, vessel, mucous gland, and extracellular 
matrix is prominent in asthmatic airways.
24 The pathological 
changes within the airways that are associated with asthma and 
COPD are similar.
25,26 Based on the complexities of the relation-
ships among the clinico-pathobiological features of the two dis-
eases, the ‘Dutch hypothesis’ was proposed and updated.
27 This 
hypothesis suggests that asthma and COPD are different expres-
sions of a single disease entity. In contrast, the ‘British hypothe-
sis’ states that asthma and COPD are separate clinical entities 
with similar symptoms.
28 The general consensus under either 
hypothesis is that similar mechanisms are involved in the patho-
genesis of both diseases. 
EPISODIC (TEMPORAL) CONVERGENCE OF ASTHMA AND 
COPD
Exacerbation/infection: Changes in inflammatory features and 
cytokine profiles
Exacerbations of asthma and COPD are clinically significant 
events. They are frequently triggered by viral infections of the 
airways and are associated with a decline in lung function and 
symptomatic aggravation.
6 During exacerbation, airway inflam-
mation becomes more exaggerated than in the mild and stable 
disease states, and the inflammation pattern changes.
29 Neu-
trophil recruitment is a prominent feature of acute exacerba-
tion of chronic asthma,
30 probably owing to respiratory tract in-
fection by viruses.
31,32 Furthermore, neutrophilic inflammation 
in the absence of eosinophils is largely present in sudden-onset 
fatal asthma, and neutrophil numbers are highly elevated in sta-
tus asthmaticus.
30,33 Thus, severe and fatal asthma may be medi-
ated by neutrophils, which is quite different from the classical 
Th2-driven eosinophilic form of the disease. In COPD patients, 
an allergic profile of inflammation can occur, particularly dur-
ing exacerbation. Airway eosinophilia is observed in chronic 
bronchitic patients with exacerbation and is associated with the 
upregulation of RANTES in the airway epithelium.
15,34 Recently, 
Siva et al.
35 demonstrated that the minimization of eosinophilic 
airway inflammation was associated with a reduction in severe 
COPD exacerbation. Taken together, these studies indicate that 
the inflammatory characteristics of asthma and COPD are in-
terchangeable during exacerbation and infection.
The cytokine profile is also affected by disease severity. During 
exacerbation, Th1/Th2 patterns are reversed to some degree in 
each disease. Several studies have demonstrated that the levels 
of IL-17, a cytokine that has been actively investigated in condi-
tions of chronic airway inflammation such as asthma,
36-39 were 
elevated in asthma and COPD and were correlated with the 
presence of neutrophils and the severity of loss of lung function. 
An elevated IL-17A level was associated with increased neutro-
philic inflammation during severe asthma or acute exacerba-
tion.
39 Increased IL-17A was also correlated with increased air-
way hyperresponsiveness in asthmatics.
40 These findings imply 
that IL-17 is an important mediator in neutrophilic asthma. In 
COPD, the role of IL-17 remains unclear, although the impor-
tance of IL-17 in stimulating chemokine production and the role 
of neutrophils and macrophages in promoting COPD pathogen-
esis suggest a potential connection.
41
Disease exacerbation in both asthma and COPD can lead to 
an accelerated decline in lung function.
42,43 Previous reports 
have shown an association between severe asthma exacerba-
tion and an accelerated decline in forced expiratory volume in 
1 s (FEV1), to a degree similar to that seen with smoking and 
COPD.
44 Another important observation was that the decline in 
FEV1 seen in patients with infrequent exacerbation was similar 
to that in a population without asthma. These findings suggest Overlap Between Asthma and COPD AAIR 
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that repetitive episodes of exacerbation may result in fixed air-
flow obstruction in asthma and contribute to the phenotypic 
overlap between asthma and COPD.
 
CONVERGENCE OF ASTHMA AND COPD ON A 
CONTINUUM
Severe/refractory asthma: Alveolar (parenchymal) destruction
Destructive changes to the alveolar parenchyma, as in emphy-
sema, are a representative characteristic of COPD.
45 Emphyse-
ma is initially centrilobular, but can become panlobular in se-
vere forms of the disease. In asthma, structural changes such as 
abnormal alveolar attachments and a decrease in elastic fibers 
can occur in the parenchyma, but these seem to be localized to 
the peribronchiolar spaces.
46 These changes lead to decreased 
distensibility and increased collapsibility in asthmatic emphy-
sema, whereas loss of elastic recoil is an important factor in the 
dynamic collapse of the airway in COPD.
47
Currently, it is believed that there are at least two major patho-
physiological mechanisms responsible for the development of 
emphysema: protease–antiprotease imbalance and apoptosis 
of structural cells.
48 Increased elastin degradation and enhanced 
expression of proteases have been documented in asthma pa-
tients.
22,25 In IL-13-overexpressing transgenic mice, IL-13 in-
duced emphysema and the expression of a variety of matrix me-
talloproteinases (MMPs) and cathepsins.
49 Interventions that 
neutralized MMPs or cathepsins dramatically ameliorated IL-
13-induced emphysematous responses. This suggests that IL-
13, which is implicated in the pathogenesis of asthma, has the 
ability to induce an alveolar remodeling response in asthmatics. 
In human asthma patients, the numbers of eosinophils, CD4
+ T-
cells, and macrophages were increased in alveolar tissue at the 
time symptoms appeared.
50,51 Taken together, these data indi-
cate that the destruction of distal airways is a consequence of a 
chronic, long-lasting injury which can significantly affect lung 
function in both COPD and asthma. Furthermore, the degree of 
eosinophilic inflammation correlated positively with lung vol-
ume in asthma.
52
Asthma-like COPD: Airway remodeling
Airway remodeling is a characteristic feature of asthma and 
has important functional implications. The structural changes 
include epithelial detachment, subepithelial fibrosis, increased 
airway smooth muscle (ASM) mass, decreased distance between 
epithelium and ASM cells, goblet cell hyperplasia, mucus gland 
hyperplasia, proliferation of blood vessels, airway edema, and 
changes in cartilage.
53 Each can contribute to airway hyperre-
activity (AHR) and may eventually lead to irreversible airflow 
obstruction with disease progression.
53 In COPD, there is also a 
thickening of the airway wall, involving the epithelium, reticu-
lar basement membrane, ASM, and mucous glands, although it 
is not as prominent as in asthma.
54 In addition, there is evidence 
for remodeling, fibrosis, and inflammation in these structures, 
albeit with patterns different from those seen in asthmatics.
54-56 
Furthermore, bronchodilator reversibility and AHR may be 
present in a significant proportion of COPD patients.
57 Poorer 
pulmonary function is associated with a greater magnitude of 
AHR, and increasing severity of AHR is associated with faster 
rates of decline in lung function in continuing smokers.
58 Pa-
tients with COPD who presented reversibility were often classi-
fied as having an ‘asthmatic’ component in contrast to ‘pure’ or 
‘true’ COPD. Small-scale clinical trials assessing inhaled steroids 
in COPD indicated that they should not be prescribed for pa-
tients who had no acute response to inhaled bronchodilators or 
oral corticosteroids.
59 However, many recent studies have sug-
gested that COPD patients without AHR or bronchodilator/oral 
steroid responses can be treated with these drugs.
60-62
The relationship between structural alterations and airway re-
sponsiveness in COPD patients has been investigated. Chanez 
et al.
16 reported that COPD patients with asthma-like features 
such as eosinophilia and airway hyperresponsiveness had thick-
er basement membranes than COPD patients without these 
features. There was more ASM in the small airways of COPD 
patients than in controls, but ASM was less prominent than in 
asthma.
63 Mathematical modeling has indicated that an increase 
in muscle mass is the most important contributor to airway hy-
perresponsiveness.
64 These findings suggest that COPD with 
airway remodeling is a severe phenotype and part of the overlap 
between COPD and asthma.
 
RECENT CONCEPTS FOR ASTHMA AND COPD 
TREATMENT: COMMON THERAPEUTIC TARGETS
Clinical recognition of the overlap between asthma and COPD 
is based on inflammatory features. Inflammation in asthma is 
associated with increased airway hyperresponsiveness, which 
leads to recurrent episodes of wheezing, breathlessness, chest 
tightness, and coughing, particularly at night or in early morn-
ing.
65 This inflammation is present even in those with very mild 
asthma and is unique in that the airway wall is infiltrated by Th2 
lymphocytes, eosinophils, macrophages/monocytes, and mast 
cells.
65 In contrast, the pathological hallmarks of COPD are de-
struction of the lung parenchyma (pulmonary emphysema) and 
inflammation of the peripheral airways (respiratory bronchiol-
itis) and central airways, along with parenchymal inflamma-
tion.
66,67 There is a marked increase in macrophages and neu-
trophils in the bronchoalveolar lavage fluid and induced spu-
tum.
66,67 Given that asthma and COPD are both pulmonary dis-
orders characterized by various degrees of inflammation and 
tissue remodeling, they present common therapeutic targets.
MOLECULAR TARGETS IN ASTHMA AND COPD
Many external inflammatory signals such as viral and bacteri-Kim et al. Volume 2, Number 4, October 2010
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al infections, allergens, cytokines, and growth factors can acti-
vate intracellular kinases, following binding to transmembrane 
receptors on responsive cells.
68 Intracellular kinase pathways 
play critical roles in a majority of pathobiological events, includ-
ing transcription, translation, cell migration, apoptosis, and cel-
lular production and secretion of mediators.
69,70 Studies have 
focused on the elucidation of these signaling pathways in order 
to find novel therapeutic targets common to both asthma and 
COPD. The kinases investigated include mitogen activated pro-
tein kinases such as p38, ERK, and JNK; inhibitor of κB kinase 
2/NF-κB; phosphoinositol-3 kinase; and signal-specific Janus 
kinases and signal transducers and activators of transcription.
71
One inflammatory mediator common to both airway diseas-
es is adenosine, making its receptor signaling pathway a thera-
peutic target for asthma and COPD. Adenosine levels were in-
creased in the plasma, lavage fluid, and exhaled breath conden-
sate of patients with asthma and COPD, and in animal models 
that exhibited features of chronic airway disease.
72 Moreover, 
the inhalation of adenosine induced bronchoconstriction in 
patients with asthma and COPD.
73 A non-selective adenosine 
receptor antagonist, theophylline, improves lung function and 
symptoms in asthma and COPD.
72,73 Furthermore, adenosine 
receptors are expressed on most, if not all, inflammatory and 
stromal cell types involved in the pathogenesis of asthma and 
COPD. Extracellular adenosine elicits its effects by interacting 
with four adenosine receptors: A1R, A2AR, A2BR, and A3R.
74 
Adenosine receptor signaling systems are complex, displaying 
different and specific actions in various inflammatory respons-
es. Studies in animal models of airway disease have suggested 
that A1, A3, and A2B antagonists may be useful for the treatment 
of asthma and COPD, although their therapeutic efficacy re-
mains to be fully evaluated. Various selective adenosine recep-
tor antagonists are under preclinical or clinical studies in pa-
tients with asthma and/or COPD.
CONCLUSIONS
Asthma and COPD are complex, multifactorial airway diseas-
es associated with significant morbidity and mortality. Despite 
their distinct clinical phenotypic features, there is considerable 
overlap of symptoms and pathogenesis, and several hypotheses 
have been proposed regarding the status of asthma and COPD 
as single disease entities. Asthma and COPD may have distinct 
or common origins; nevertheless, clinical overlap can result 
owing to similar structural alterations that can develop in both 
diseases as a consequence of chronic inflammatory tissue inju-
ry, especially in the most severe cases. Overlapping features may 
occur not only in a permanent form but also as a transient symp-
tom, as in exacerbation. In accordance with this, recent thera-
peutic approaches have concentrated on a target common to 
the pathogenesis of both asthma and COPD. Possible candidate 
targets include the adenosine receptor system and various ki-
nase pathways, and many selective inhibitors of adenosine re-
ceptors and kinases are in preclinical or clinical trials. There re-
mains a need to extend novel drug development and investigate 
the mechanisms and treatment of overlapping asthma and 
COPD.
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